Drug Trial Radar · NCT04864743
A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Last checked: Nov 19, 2026Latest source record: Sep 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Jun 22, 2021
Primary completion
Oct 17, 2021
Study completion Oct 17, 2021
Sponsor
- Lead sponsor
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to evaluate the Pharmacokinetics,Safety and tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in patients with severe hemophilia A. The secondary objectives are to monitor anti-durg antibodies and anti-PEG antibodies levels in patients with severe hemophilia A
Conditions
- Severe Hemophilia A
Interventions
ADVATEDrug
a single dose.
FRSW117Drug
a single dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2
- Arm1 - T½ from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2
- Arm1 - CL from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2
- Arm1 - MRT from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2
- Arm1 - Incremental recovery from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion forArm1; Pre-dose to 288 hours after the end of the infusion for Arm2
- Arm1 - Cmax from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
- Arm1 - T½ from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
- Arm1 - CL from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
- Arm1 - MRT from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
- Arm1 - Incremental recovery from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
- Number of participants with treatment-emergent adverse events (TEAEs).Time frame: assessed up to four weeks after FRSW117 administration.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital of Southern Medical University
Guangzhou, Guangzhou, China
People's Hospital of Zhengzhou
Zhengzhou, Henan, China
Jinan central hospital
Jinan, Shandong, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.